Purification of Cyclotron-produced 203Pb for Labeling Herceptin

Overview

Journal Nucl Med Biol

Publisher Elsevier

Specialties Biology
Nuclear Medicine

Date 2005 Apr 12

PMID 15820766

Citations 9

Authors

Kayhan Garmestani

Diane E Milenic

Erik D Brady

Paul S Plascjak

Martin W Brechbiel

Affiliations

Soon will be listed here.

Abstract

A simple and rapid procedure was developed for the purification of cyclotron-produced 203Pb via the 203Tl(d,2n) 203Pb reaction. A Pb(II) selective ion-exchange resin, with commercial name Pb Resin from Eichrom Technologies, Inc., was used to purify 203Pb from the cyclotron-irradiated Tl target with excellent recovery of the enriched Tl target material. The purified 203Pb was used to radiolabel the monoclonal antibody Herceptin. The in vitro and in vivo properties of the 203Pb radioimmunoconjugate were evaluated.

Citing Articles

SPECT/CT imaging of EGFR-positive head and neck squamous cell carcinoma patient-derived xenografts with Pb-PSC-panitumumab in NRG mice.

Sarrami N, Nelson B, Leier S, Wilson J, Chan C, Meens J EJNMMI Radiopharm Chem. 2024; 9(1):79.

PMID: 39589608 PMC: 11599518. DOI: 10.1186/s41181-024-00313-8.

Production, purification, and radiolabeling of the Pb/Pb theranostic pair.

McNeil B, Robertson A, Fu W, Yang H, Hoehr C, Ramogida C EJNMMI Radiopharm Chem. 2021; 6(1):6.

PMID: 33527221 PMC: 7851237. DOI: 10.1186/s41181-021-00121-4.

Preclinical Evaluation of Pb-Labeled Low-Molecular-Weight Compounds for Targeted Radiopharmaceutical Therapy of Prostate Cancer.

Banerjee S, Minn I, Kumar V, Josefsson A, Lisok A, Brummet M J Nucl Med. 2019; 61(1):80-88.

PMID: 31253744 PMC: 6954458. DOI: 10.2967/jnumed.119.229393.

Evaluation of a Novel Pb-203-Labeled Lactam-Cyclized Alpha-Melanocyte-Stimulating Hormone Peptide for Melanoma Targeting.

Yang J, Xu J, Cheuy L, Gonzalez R, Fisher D, Miao Y Mol Pharm. 2019; 16(4):1694-1702.

PMID: 30763112 PMC: 6443429. DOI: 10.1021/acs.molpharmaceut.9b00025.

Exploration of a F(ab') Fragment as the Targeting Agent of α-Radiation Therapy: A Comparison of the Therapeutic Benefit of Intraperitoneal and Intravenous Administered Radioimmunotherapy.

Milenic D, Kim Y, Baidoo K, Wong K, Barkley R, Delgado J Cancer Biother Radiopharm. 2018; 33(5):182-193.

PMID: 29916748 PMC: 6011368. DOI: 10.1089/cbr.2018.2434.